Investigational drug · Phase 2
PBT434
Also called: ATH434
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple System Atrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
3
Any phase or sponsor naming "PBT434"
First trial start
2022
Jul 1, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PBT434", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple System Atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "PBT434" as an intervention, largest first.
Alterity TherapeuticsIndustry
NCT05109091 · 77 participants · Start Jul 1, 2022 · Primary completion Nov 28, 2024
Drug: ATH434 dose level 1; ATH434 dose level 2 and 1 more · For: Multiple System Atrophy
Sites: La Jolla, California; Chicago, Illinois; Baltimore, Maryland · 23 sites in all
- Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in FranceEnrolling by invitation
Alterity TherapeuticsIndustry
NCT07729852 · 7 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 2029
Drug: ATH434 · For: Multiple System Atrophy
Sites: Toulouse, France; Bordeaux, France; Marseille, France · 4 sites in all
Alterity TherapeuticsIndustry
NCT07531433
Drug: ATH434 · For: Multiple System Atrophy
Newest research
PubMed records naming it or its code names, newest first.
- Potent antioxidant and mitochondrial-protective effects of ATH434, a moderate affinity iron chaperone.
Bailey DK, Nihlawi R, Bradbury MJ, et al. · J Biol Chem 2025
- ATH434, a promising iron-targeting compound for treating iron regulation disorders.
Pall AE, Bond S, Bailey DK, et al. · Metallomics 2024
- ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism.
Beauchamp LC, Liu XM, Vella LJ, et al. · Neurotherapeutics 2022
- The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy.
Finkelstein DI, Shukla JJ, Cherny RA, et al. · J Parkinsons Dis 2022
- ATH434 Reduces α-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy.
Heras-Garvin A, Refolo V, Schmidt C, et al. · Mov Disord 2021
- Correction to: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
Finkelstein DI, Billings JL, Adlard PA, et al. · Acta Neuropathol Commun 2021
Also in development for Multiple System Atrophy
- AmlenetugLu AF82422Phase 32 trials
H. Lundbeck A/S · Multiple System Atrophy
- Foralumab NasalPhase 22 trials
Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- TEV-56286EmrusolminPhase 22 trials
Teva · Multiple System Atrophy
- exidavnemabPhase 21 trial
BioArctic AB · Parkinson Disease, Multiple System Atrophy
- TAK-341MEDI1341Phase 21 trial
Takeda · Multiple System Atrophy
- YA-101Phase 21 trial
Dasher Neuroscience Inc. · Multiple System Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.